Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Long-Term Investments: 2022-2024

Historic Long-Term Investments for OptimizeRx (OPRX) over the last 3 years, with Q2 2024 value amounting to $434000.0.

  • OptimizeRx's Long-Term Investments changed N/A to $434000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $434000.0, marking a year-over-year change of. This contributed to the annual value of $568000.0 for FY2023, which is 9898.39% down from last year.
  • According to the latest figures from Q2 2024, OptimizeRx's Long-Term Investments is $434000.0.
  • In the past 5 years, OptimizeRx's Long-Term Investments registered a high of $55.9 million during Q4 2022, and its lowest value of $434000.0 during Q2 2024.
  • Over the past 3 years, OptimizeRx's median Long-Term Investments value was $568000.0 (recorded in 2023), while the average stood at $11.6 million.
  • Over the last 5 years, OptimizeRx's Long-Term Investments had its largest YoY gain of 9898.39% in 2023, and its largest YoY loss of 9898.39% in 2023.
  • OptimizeRx's Long-Term Investments (Quarter) stood at $55.9 million in 2022, then plummeted by 98.98% to $568000.0 in 2023, then dropped by 23.59% to $434000.0 in 2024.
  • Its Long-Term Investments was $434000.0 in Q2 2024, compared to $501000.0 in Q1 2024 and $568000.0 in Q4 2023.